Compass Therapeutics
CMPX · Nasdaq · United States
Share price · CMPX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when CMPX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 16 Nov 2026-14.5%
Nothing announced by CMPX that day or the session before.
- 5 Oct 2026+12.1%
Nothing announced by CMPX that day or the session before.
- 1 Oct 2026-13.4%
Nothing announced by CMPX that day or the session before.
- 22 Sep 2026-31.9%
- 12 Aug 2026+7.7%
Nothing announced by CMPX that day or the session before.
- 7 Aug 2026+8.0%
- 5 Aug 2026-4.5%
Nothing announced by CMPX that day or the session before.
- 27 Apr 2026-64.4%
- 20 Apr 2026-9.8%
Nothing announced by CMPX that day or the session before.
- 17 Apr 2026-8.1%
Nothing announced by CMPX that day or the session before.
Share of unusual movement by asset
For each asset, the share of CMPX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $22M | $41M+ $122M short-term inv. | $27M-$16M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $20M | $35M+ $144M short-term inv. | $25M-$15M operating cash flow | report ↗ |
| 2026-Q1 | — | $13M | $55M+ $140M short-term inv. | $18M-$17M operating cash flow | report ↗ |
| 2025-Q3 | $0 | $13M | $46M+ $174M short-term inv. | $14M-$11M operating cash flow | report ↗ |
| 2025-Q2 | $0 | $16M | $23M+ $78M short-term inv. | $20M-$12M operating cash flow | report ↗ |
| 2025-Q1 | — | $13M | $41M+ $72M short-term inv. | $17M-$13M operating cash flow | report ↗ |
| 2024-Q3 | $0 | $8.6M | $37M+ $99M short-term inv. | $10M-$11M operating cash flow | report ↗ |
| 2024-Q2 | $0.8M | $11M | $19M+ $127M short-term inv. | $13M-$11M operating cash flow | report ↗ |
| 2024-Q1 | — | $9.5M | $24M+ $133M short-term inv. | $11M-$14M operating cash flow | report ↗ |
| 2023-Q3 | $0 | $8.8M | $30M+ $133M short-term inv. | $10.0M-$5.9M operating cash flow | report ↗ |
| 2023-Q2 | $0 | $10M | $19M+ $149M short-term inv. | $11M-$10M operating cash flow | report ↗ |
| 2023-Q1 | — | $6.6M | $27M+ $148M short-term inv. | $7.8M-$12M operating cash flow | report ↗ |
| 2022-Q3 | — | $9.8M | $16M+ $104M short-term inv. | $12M-$11M operating cash flow | report ↗ |
| 2022-Q2 | — | $5.9M | $26M+ $106M short-term inv. | $8.5M-$4.6M operating cash flow | report ↗ |
| 2022-Q1 | — | $4.4M | $136M | $7.2M-$7.9M operating cash flow | report ↗ |
| 2021-Q3 | — | $3.1M | $26M | $6.0M-$3.5M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0 | $56M | $31M+ $178M short-term inv. | $17M-$49M operating cash flow | report ↗ |
For FY2025, Compass Therapeutics reported revenue of $0M, a 100.0% YoY decrease from $0.85M, and R&D spend of $55.97M, up 32.2% YoY. The company ended the period with cash and equivalents of $30.64M and reported a net loss of $66.49M (quarterly net burn of $66.49M).
Compass is a clinical-stage oncology biopharmaceutical company advancing four product candidates. Its lead bispecific antibody tovecimig (DLL4 x VEGF-A) met the primary endpoint in a randomized Phase 2/3 biliary tract cancer trial, with an ORR of 17.1% versus 5.3% for paclitaxel alone (p=0.031), and PFS and OS analyses are expected in April 2026; a Phase 2 CRC monotherapy study showed a 5% ORR, 68% DCR, median PFS of 3.9 months, and median OS of 10.2 months. CTX-471, a CD137 agonist, has shown monotherapy responses in post-PD-1/PD-L1 patients, with a Phase 2 basket study in NCAM+ tumors planned for mid-2026. CTX-8371 (PD-1 x PD-L1) is in Phase 1 with cohort expansions underway in NSCLC and TNBC, while CTX-10726 (PD-1 x VEGF-A) received FDA IND clearance and entered Phase 1 in early 2026.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $0.8M | $42M | $43M+ $83M short-term inv. | $12M-$45M operating cash flow | report ↗ |
| 2023-FY | $0 | $38M | $24M+ $128M short-term inv. | $11M-$41M operating cash flow | report ↗ |
| 2022-FY | — | $30M | $35M+ $152M short-term inv. | $9.8M-$34M operating cash flow | report ↗ |
| 2021-FY | — | $20M | $145M+ $0 short-term inv. | $21M-$20M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 5 purchases ($103K), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-17 | Lerner Neil · Chief Accounting Officer | Open-market purchase | 10,000 | $0.59 | $6K | Form 4 |
| 2026-10-01 | Lerner Neil · Chief Accounting Officer | Open-market purchase | 20,000 | $0.92 | $18K | Form 4 |
| 2026-09-24 | Lerner Neil · Chief Accounting Officer | Open-market purchase | 2,500 | $1.14 | $3K | Form 4 |
| 2026-04-29 | Anderman Jonathan · General Counsel | Open-market purchase | 25,000 | $1.89 | $47K | Form 4 |
| 2026-04-29 | Lerner Neil · Chief Accounting Officer | Open-market purchase | 15,000 | $1.89 | $28K | Form 4 |
| 2026-04-29 | Lerner Neil · Chief Accounting Officer | Award / grant | 15,000 | $1.89 | $28K | Form 4 |
| 2026-04-29 | Anderman Jonathan · General Counsel | Award / grant | 25,000 | $1.89 | $47K | Form 4 |
| 2026-02-08 | Schuetz Thomas J. · director, CHIEF EXECUTIVE OFFICER | Tax withholding | 36,687 | $6.52 | $239K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 200 reporting institutions held 173.2M shares ($917.7M, 96.2% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | TANG CAPITAL MANAGEMENT LLC | 16,790,809 | $88.8M |
| 2 | ORBIMED ADVISORS LLC | 15,219,994 | $80.5M |
| 3 | SUVRETTA CAPITAL MANAGEMENT, LLC | 14,307,379 | $75.7M |
| 4 | Vivo Capital, LLC | 9,545,466 | $50.5M |
| 5 | BlackRock, Inc. | 9,506,080 | $50.3M |
| 6 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 8,486,500 | $44.9M |
| 7 | ENAVATE SCIENCES GP, LLC | 7,788,150 | $41.2M |
| 8 | BVF INC/IL | 7,764,842 | $41.1M |
| 9 | STATE STREET CORP | 6,694,976 | $35.4M |
| 10 | VANGUARD CAPITAL MANAGEMENT LLC | 6,037,175 | $31.9M |
| 11 | RTW INVESTMENTS, LP | 4,186,599 | $22.1M |
| 12 | DEERFIELD MANAGEMENT COMPANY, L.P. | 3,606,000 | $19.1M |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 3,565,770 | $18.9M |
| 14 | Rock Springs Capital Management LP | 3,305,308 | $17.5M |
| 15 | Logos Global Management LP | 3,150,000 | $16.7M |